A former Roivant spinout bets on AI-designed drugs for immune conditions
A former Roivant spinout bets on AI-designed drugs for immune conditions
A former Roivant spinout bets on AI-designed drugs for immune conditions
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.